---
schema_version: "secwatch.filing_event.v1"
accession: "0001077183-25-000172"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T01:51:40.845683+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics Q3 revenue up 12% to $188M; net loss widens 53% to $27M

## Summary
- Revenue of $188M, +12% YoY; clinical revenue +18% and NGS +24% to ~1/3 of clinical.
- Net loss $27M vs $18M, up 53%; adjusted EBITDA $12.2M, down 9% from $13.4M.
- Reaffirmed FY 2025 guidance: revenue $720-726M, net loss $(116)-(108)M, adj EBITDA $41-44M.
- OpEx +12% YoY, includes $7.1M impairment charge on Trapelo held-for-sale.

## SEC filing metadata
- accession: 0001077183-25-000172
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000107718325000172/0001077183-25-000172-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000107718325000172/neo-20251028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001077183-25-000172
- JSON: https://secwatch.observer/filing/0001077183-25-000172.json
- Plain text: https://secwatch.observer/filing/0001077183-25-000172.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.